Compare Forgent Power Solutions Inc. Class A Common Stock (FPS) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Forgent Power Solutions Inc. Class A Common Stock vs Heron Therapeutics Inc — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $32.31 (market cap $9.93B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.18M). The key difference: Forgent Power Solutions Inc. Class A Common Stock is far larger — about 133.9× Heron Therapeutics Inc's market cap, and Forgent Power Solutions Inc. Class A Common Stock is more actively traded (7,516,726 versus 1,857,401). Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Heron Therapeutics Inc for 36 Days on average.
| FPS | HRTX | |
|---|---|---|
Market Cap | $9.93B | $74.18M |
Volume | 7,516,726 | 1,857,401 |
Sector | Industrials | Health |
52-Week High | $64.59 | $1.49 |
52-Week Low | $27.97 | $0.27 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $10.54B | $180.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.
FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Forgent Power Solutions Inc. Class A Common Stock
Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.
Read more on FPS →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
